Edmond DE Rothschild Holding S.A. raised its position in Merck & Company, Inc. (NYSE:MRK) by 1.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,065,493 shares of the company’s stock after buying an additional 14,340 shares during the period. Merck & accounts for about 1.8% of Edmond DE Rothschild Holding S.A.’s holdings, making the stock its 10th largest position. Edmond DE Rothschild Holding S.A.’s holdings in Merck & were worth $67,700,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Norges Bank purchased a new position in shares of Merck & during the fourth quarter worth approximately $1,628,824,000. Dodge & Cox purchased a new position in shares of Merck & during the fourth quarter worth approximately $821,068,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in shares of Merck & during the fourth quarter worth approximately $252,822,000. Bank of Montreal Can boosted its position in shares of Merck & by 49.7% in the first quarter. Bank of Montreal Can now owns 8,991,093 shares of the company’s stock worth $571,295,000 after buying an additional 2,983,319 shares during the period. Finally, Canada Pension Plan Investment Board boosted its position in shares of Merck & by 70.4% in the first quarter. Canada Pension Plan Investment Board now owns 5,568,791 shares of the company’s stock worth $353,841,000 after buying an additional 2,300,200 shares during the period. 73.73% of the stock is owned by hedge funds and other institutional investors.

Merck & Company, Inc. (NYSE MRK) traded up 0.95% on Friday, reaching $62.77. The company’s stock had a trading volume of 1,773,220 shares. The firm’s 50 day moving average price is $63.46 and its 200-day moving average price is $63.80. Merck & Company, Inc. has a 52 week low of $58.29 and a 52 week high of $66.80. The company has a market capitalization of $171.20 billion, a price-to-earnings ratio of 33.98 and a beta of 0.80.

Merck & (NYSE:MRK) last released its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $0.14. The firm had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter last year, the firm earned $0.93 earnings per share. On average, equities analysts predict that Merck & Company, Inc. will post $3.87 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Thursday, September 14th. This represents a $1.88 dividend on an annualized basis and a yield of 3.02%. Merck &’s payout ratio is 76.11%.

ILLEGAL ACTIVITY NOTICE: “Merck & Company, Inc. (NYSE:MRK) Stake Raised by Edmond DE Rothschild Holding S.A.” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/merck-company-inc-nysemrk-stake-raised-by-edmond-de-rothschild-holding-s-a/1475306.html.

A number of equities analysts recently commented on MRK shares. Jefferies Group LLC restated an “underperform” rating and set a $51.00 target price (down from $52.00) on shares of Merck & in a report on Saturday, April 22nd. BMO Capital Markets restated an “outperform” rating and set a $70.00 target price on shares of Merck & in a report on Sunday, April 23rd. Zacks Investment Research upgraded Merck & from a “hold” rating to a “buy” rating and set a $72.00 target price for the company in a report on Wednesday, May 10th. Cowen and Company restated a “market perform” rating and set a $70.00 target price (up from $68.00) on shares of Merck & in a report on Thursday, May 11th. Finally, J P Morgan Chase & Co raised their target price on Merck & from $74.00 to $76.00 and gave the company an “overweight” rating in a report on Thursday, May 11th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the stock. Merck & presently has a consensus rating of “Hold” and an average price target of $69.80.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.